UE-2343

Actinogen Medical's Xanamem (emestedastat) has been granted a unique nonproprietary name by the World Health Organization, recognizing it as a first-in-class 11β-HSD1 enzyme inhibitor.

Acumen Pharmaceuticals' sabirnetug demonstrated a favorable safety profile in a Phase 1 clinical trial for Alzheimer's disease, marking a significant step in its development.

Actinogen Medical Limited has initiated a significant phase 2b/3 trial for its Alzheimer's treatment, Xanamem, with the first US participant enrolled. The trial, spanning 25 sites in the US and Australia, aims to assess the drug's effects on cognitive and functional measures in patients, with interim results anticipated in 2025 and final results in 2026.

Actinogen Medical has reported positive investor confidence following a successful General Meeting, supporting the ongoing development of Xanamem.

Actinogen Medical Limited has announced optimizations to its XanaMIA Phase 2b trial for mild-to-moderate Alzheimer's disease, reducing costs by AUD 30 million and speeding up initial results. The trial now focuses on a 10 mg dose group, enrolling 220 patients, and includes Australian sites for the first 100 patients. Additionally, the XanaCIDD trial for cognitive impairment associated with depression has expanded to include UK sites, with results expected by mid-2024.